GnRH Therapy on Cognition in Down Syndrome

Recruiting Phase 2 Phase 3 Interventional Study
Down Syndrome Cognitive Decline Alzheimer Disease, Early Onset Olfaction Disorders
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
16 – 50
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
56 (estimated)
Sponsor
Nelly Pitteloud · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defect…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of trisomy 21 * Verbal expression (ability to follow the procedures of the study) * Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: …
Contacts

Pulse-UP study

+41 21 314 06 25

pulseup@chuv.ch

CONTACT

Tommaso Todisco, MD

+41 79 556 8513

tommaso.todisco@chuv.ch

CONTACT